Amylin, or islet amyloid polypeptide, is a 37-amino acid hormone secreted by the pancreas [1, 2] . Previously reported actions of this peptide include the regulation of insulin secretion [3] and the inhibition of glucose uptake [4] . Amylin shares a high degree of sequence homology (approximately 50 %) with calcitonin gene-related peptide (CGRP) and both of these peptides elicit marked hypotension in rats [5] [6] [7] [8] . The hypotensive action of amylin is blocked by the CGRP antagonist fragment, CGRP [6] and is consequently thought to be mediated through vascular CGRP-receptors. Although rat amylin and salmon calcitonin share little sequence homology, there is evidence that these peptides compete with high affinity for a single class of binding sites in regions of the rat brain [9] [10] [11] . Furthermore, calcitonin also shares some physiological effects with both CGRP and amylin. For example all three peptides have been shown to increase plasma renin activity in either man [12] [13] [14] or rats [15] .
Summary Amylin (or islet amyloid polypeptide) has been reported to have binding sites in the central nervous system and the kidney and has been shown to activate plasma renin. It has been postulated that this peptide may be an important mechanistic link between hypertension and diabetes in the insulin resistance syndrome. To explore this issue, the effects of rat amylin on mean arterial blood pressure were investigated in anaesthetised rats. Amylin elicited a pressor response of approximately 10 mmHg (maximal at 100 pmol ⋅ kg -1 ) which was apparent within 30-60 s and persisted over 15 min. At higher concentrations amylin elicited a hypotensive response (negative log IC 50 8 .52 mol ⋅ kg -1 ). The novel amylin receptor antagonist AC413 (12 nmol ⋅ kg -1 ⋅ min -1 ) reduced the pressor response but not the hypotensive effects of amylin. The peptide antagonist calcitonin gene-related peptide (CGRP) (12 ) reduced the pressor response elicited by amylin and also antagonized the hypotensive effect of amylin. Pre-treatment of animals with the ganglion blocker mecamylamine (3 mg ⋅ kg -1 s. c.) reduced the pressor effect of amylin. Following the administration of the angiotensin converting enzyme inhibitor ramiprilat (300 nmol ⋅ kg -1 i. v.) the pressor response to amylin was reduced. Salmon calcitonin also elevated blood pressure in the anaesthetised rat; doses of amylin and salmon calcitonin associated with a pressor effect were associated with increases in plasma renin activity. We conclude that amylin may act centrally to elevate blood pressure in the anaesthetised rat, possibly through activation of the renin angiotensin system. [Diabetologia (1997) 40: 256-261] Keywords Amylin, hypertension, calcitonin, ACE inhibition, calcitonin gene related peptide.
antagonist, AC413 [15] , and the inactive peptide fragment, CGRP which acts as an amylin antagonist at relatively high concentrations [16] . Since amylin-selective binding sites have been found in rat brain [9] [10] [11] and kidney [15] and amylin has also been shown to activate plasma renin activity in both rats [15] and humans [12] we have also investigated the effect of ganglion blockade and angiotensin-converting enzyme (ACE)-inhibition on the blood pressure response to amylin.
Materials and methods
Animals. Male Sprague-Dawley rats (280-360 g) were housed with a photoperiod of 12 h light-12 h dark at 20 ± 1°C. Animals were allowed access to water and food (GR2 pellets; ClarkKing and Co., Melbourne, Australia) ad libitum. On the day of use the animals were anaesthetised with urethane (1.3-1.5 g ⋅ kg -1 i. p.) and the depth of anaesthesia was monitored with paw pinch and corneal reflex tests. Animals were placed on a heated table and body temperature monitored continuously and maintained between 35 and 37°C. Both the left jugular and carotid arteries were cannulated with polyethylene catheters (SP37 Dural plastics, Auburn, Australia). The jugular cannula was flushed with heparin (500 U per rat) and the preparations allowed at least 3 min to equilibrate. Agonists or vehicle (Haemaccel; Behring, Frankfurt, Germany) were added as a bolus (less than 0.15 ml over 10 s) into the jugular cannula at approximately 20-min intervals. Changes in arterial pressure were monitored (10 samples ⋅ s -1 ) via Gould-Statham (model P-23, Cleveland, Ohio, USA) or disposable (model Baxter Healthcare Round Lake, IL, USA) pressure transducers coupled to a MacLab/8 data acquisition system (AD Instruments, Castle Hill, N. S. W., Australia).
Drugs used included rat amylin (Bachem, Torrance, California, USA, AC413 [a chimera of rat amylin and salmon calcitonin, ATQRLANFLVRLQTYPRTNVGANTY], Amylin Corporation, San Diego, Calif., USA), human angiotensin I (Auspep, Melbourne, Australia), rat CGRP (Amylin Corporation), atropine sulphate (Astra Pharmaceuticals, Abbotsford, Australia), ramiprilat (Hoechst, Frankfurt, Germany) rat a -CGRP (Bachem), rat calcitonin (Bachem), mecamylamine HCl (Sigma Chemical Co., St. Louis, Mo., USA), phenylephrine (Sigma Chemical Co.) and salmon thyrocalcitonin (Sigma Chemical Co.). All drugs were made up in vehicle on the day of use.
Antagonists or vehicle were infused at 7 m l ⋅ min -1 (Razel model A-99 syringe pump, Razel, Stamford, CT, USA) into the jugular cannula for 60 min prior to the addition of agonists. Antagonists were continuously infused into animals for a further 3 h. No animal received more than one agonist. In a separate series of experiments, plasma renin activity (PRA) was measured in anaesthetised rats 5 min after administration of vehicle, rat amylin or salmon calcitonin. PRA was assessed as generation of angiotensin I as measured by radioimmunoassay [17] . Mean arterial pressure (MAP) was calculated over 10 s periods. Peak changes in MAP were used for analysis and defined as the greatest increase in MAP occurring within 5 min of addition of the agonist.
Ganglion blockade. One group of rats were ganglion blocked with mecamylamine (3 mg ⋅ kg -1 , s. c.), given atropine (0.4 mg ⋅ kg -1 , s. c.) [18, 19] and allowed to equilibrate for 30 min prior to the addition of agonists. In an additional group of ganglion blocked rats, MAP was raised with a constant infusion of phenylephrine (60 nmol ⋅ kg
ACE-inhibition.
The ACE inhibitor, ramiprilat (300 nmol ⋅ kg -1 i. v. bolus), was administered to rats and 10 min later the effects of agonists or of angiotensin I were tested. This dose of ramiprilat was sufficient to reduce the pressor response to angiotensin I (100 mg ⋅ kg -1
) by 80 % for at least 120 min (n = 5) [20] .
Statistical analysis
Changes in MAP following the administration of antagonists, ramiprilat or mecamylamine were analysed using a paired ttest (Statview SE and Graphics, Brainpower, Calabasas, California, USA). Responses to each concentration of amylin were compared (Student's t-test) to equivalent vehicle-only time controls. Hypotensive response data were analysed using FLEXIFIT to provide estimates of IC 50 and potency ratios [21, 22] . Differences between the pressor effect of amylin in the control and treatment groups were compared by use of a one-way analysis of variance (Statview SE and Graphics). Further analysis, due to multiple comparisons, was performed using the Fisher Least Significance Difference (PLSD) method (Statview SE and Graphics). A p-value less than 0.05 was considered statistically significant. Results for changes in MAP are expressed as mean ± SEM.
Results
Anaesthetised rats. Following anaesthesia with urethane (1.3 g ⋅ kg -1 i. p.) preparations were stable for approximately 3 h with MAP of 90 ± 4 mmHg and heart rate of 344 ± 4 beats ⋅ min -1 .
Effect of agonists.
Compared to vehicle-only time controls both amylin and salmon calcitonin (sCT) elicited significant pressor effects at 10 and 100 pmol ⋅ kg -1 (p < 0.05, see Fig. 1 for typical changes in MAP and Fig. 2 ). The effects of amylin on blood pressure were apparent within 30 to 60 s and persisted for up to 15 min (Fig. 1 ). Higher doses of amylin ( > 1 nmol ⋅ kg -1 ) reduced MAP (Fig. 2) . The pressor effects of amylin and sCT were both quantitively and qualitatively similar (0.1 nmol/kg amylin, 9.7 ± 3.8 mmHg, n = 6; 0.1 nmol/kg sCT, 11.5 ± 3.9 mmHg, n = 6), but were not additive (n = 6, 8.8 ± 2.7 mmHg). Rat calcitonin (100 pmol kg -1 ) was without significant pressor activity (n = 6, 2.2 ± 3.5 mmHg).
Effect of antagonists.
The antagonists AC413 and CGRP (12 nmol ⋅ kg ⋅ min -1 ) significantly reduced the pressor effect of amylin (Fig. 3) , but did not affect the hypotensive response to amylin (Table 1) . CGRP at a dose of 4 nmol ⋅ kg , CGRP significantly reduced the pressor effect of amylin (Fig. 3) , and also significantly antagonized the hypotensive effects of amylin (Table 1) .
Ganglion blockade. Following ganglion blockade with mecamylamine (3 mg ⋅ kg -1 s. c.) and the addition of atropine (0.4 mg ⋅ kg -1 s. c.), MAP was significantly reduced from 82 ± 8 to 50 ± 4 mmHg. The pressor effect of amylin was reduced compared with controls (Fig. 3) . The IC 50 of the hypotensive effect of amylin (Table 1) was not affected by ganglion blockade. In one group of ganglion-blocked animals phenylephrine (60 nmol ⋅ kg
) was constantly infused to increase MAP (to 97 ± 9 mmHg). In these animals the pressor effect of amylin was significantly reduced but the hypotensive effect of amylin was significantly enhanced (Table 1) .
ACE inhibition. The ACE inhibitor ramiprilat (300 nmol ⋅ kg -1 i. v.) significantly reduced basal MAP from 91 ± 7 to 65 ± 6 mmHg. Following the administration of ramiprilat the pressor response to amylin was reduced (Fig. 3) . ACE inhibition did not affect the hypotensive action of amylin (Table 1) . Ramiprilat also attenuated the pressor response to sCT (2.2 ± 2.8 mmHg, n = 6, p < 0.05 vs sCT alone).
Effects of agonists on plasma renin activity (PRA).
We measured (PRA) in a subgroup of anaesthetised rats (Table 2) . Vehicle was associated with no change in PRA whereas bolus administration of either amylin or sCT at a concentration of 1 nmol/kg which is associated with a pressor response was associated with an increase in PRA (Table 2) .
Discussion
We have shown that rat amylin elicits a pressor response in anaesthetised rats. The pressor response to amylin is reduced by the peptide antagonists AC413 and CGRP and also by ganglion blockade and ACE inhibition. Blockade of this pressor effect with peptide antagonists suggests that this rise in blood pressure involves an interaction between amylin and its receptor. The presence of high affinity amylin binding sites in the brain has been previously reported and includes sites which would have access to blood-borne peptides [9] . Salmon calcitonin has also elicited a pressor response and is consistent with its ability to interact with the amylin binding site in the ⋅ min -1 . GB was achieved by subcutaneous preadministration of mececylamine 3 mg/kg and atropine 0.4 mg/kg. Ramiprilat was infused at a bolus of 300 mg/kg. * p < 0.05 vs amylin alone brain with similar affinity to amylin [9, 10] . However, one cannot exclude that the effect of salmon calcitonin was via other calcitonin receptors which are present in the central nervous system [23] .
Although CGRP can also bind to the putative amylin receptor, it has higher affinity to the CGRP receptor which has recently been cloned [24] . Therefore, in contrast to amylin, CGRP does not elicit a pressor response at low concentrations but acts as a vasodilator, leading to reduced blood pressure via these vascular CGRP receptors [5] . Amylin interacts at higher concentrations with the CGRP receptor [6, 8, 25, 26] and this would explain the hypotensive response of submicromolar concentrations of amylin which were attenuated by CGRP (Table 1) . In contrast, the putative amylin-selective antagonist, AC413, does not affect the hypotensive response to amylin, consistent with this antagonist's low affinity for vascular CGRP-receptors.
Since high affinity salmon calcitonin-and amylinselective binding sites have been identified in the rat brain [10, 11, 23, 27 ] and blood-borne salmon calcitonin can interact with specific sites in the rat brain [27, 28] , it is possible that, at concentrations below those which activate vascular CGRP receptors, amylin may act at a central site to elicit its pressor effect. This hypothesis is consistent with our finding that the pressor responses to amylin were attenuated by ganglion blockade. Since ganglion blockade reduced MAP, and reduced renal perfusion pressure may stimulate renin release [29] thereby confounding the effects of amylin on the renin-angiotensin system, we evaluated the effects of amylin in ganglionblocked animals with raised vascular tone. In this group of animals amylin did not elicit pressor responses, but the amylin-induced hypotension was markedly enhanced. Although it is possible that, in these animals, the enhanced hypotensive effect of amylin masked the pressor effect of amylin we think it more likely that ganglion blockade directly attenuated the pressor response to amylin since the pressor effect was abolished in both ganglion-blocked and ganglion-blocked with raised vascular tone groups. As yet we have no explanation for the potentiation of the amylin-mediated depressor response following the elevation of vascular tone with phenylephrine.
Our finding that the pressor effects of amylin and of salmon calcitonin were blocked by the ACE inhibitor, ramiprilat, indicates that the pressor effect of these peptides is dependent upon a functional reninangiotensin system. This hypothesis is consistent with reports of elevated plasma renin activity in man and in rats following peripheral [12, 14, 15, 30] or central administration [30] of either of these peptides. In the present study, one cannot determine if the effect of amylin was via effects on the renin-angiotensin system at the central, systemic or renal level. We have confirmed that amylin will stimulate PRA in anaesthetised rats (Table 2) as has been previously documented [31] . These findings complement the results that our group has obtained in conscious rats [15] . Salmon calcitonin has also been previously reported to have an effect on PRA in rats [30] . Our evidence of an amylin-mediated increase in PRA is also consistent with a proposed mechanism of action of amylin in hyperamylinaemic states such as the insulin resistance syndrome [32] [33] [34] .
It has previously been shown that amylin is co-secreted with insulin [35] and that hyperinsulinaemic states are associated with hyperamylinaemia [36] . In various animal models of insulin resistance including rodents with obesity, glucose intolerance and hypertension, amylin concentrations have been reported to be markedly elevated in the subnanomolar range [37, 38] . Further evidence to indicate a role for amylin in the genesis of obesity-related hypertension has been suggested by the preliminary report in the sucrose-fed rat [39] . In these animals, the amylin antagonist, AC413, prevented the rise in blood pressure. This peptide antagonist has been reported by our These values show the negative log IC 50 (mol ⋅ kg −1 ) of amylin as mean ± SEM. All peptide antagonists were constantly infused (12 nmol ⋅ kg ). Some animals received the ACE-inhibitor, ramiprilat (300 nmol ⋅ kg −1 s. c.). Agonists were added in i. v. bolus concentrations. All estimates were from 6-8 animals.
a p < 0.05 vs control Data are mean ± SEM. a p < 0.05 vs baseline. Data are shown for plasma renin activity as ngA1 ⋅ ml
Agonists were added in i. v. bolus concentrations group to prevent amylin-induced increases in PRA [15] and in the present study was shown to attenuate the acute pressor response of amylin in the anaesthetised rat.
One must be cautious in extrapolating these results in rats to the role of amylin in man. Nevertheless, plasma amylin levels are elevated in individuals with essential hypertension [40] . Amylin has been reported to increase plasma renin concentrations in man [12] and more recent studies have indicated that this effect of amylin on renin occurs within the pathophysiological range [31] . Although blood pressure was not a major endpoint in our previous study on the effects of amylin in man, it is of interest that the amylin infusion was associated with a modest increase in blood pressure [12] .
From the present study, one cannot assume that these modest effects of amylin on systemic blood pressure would ultimately translate to the development of essential hypertension. The potential impact of only modest changes in blood pressure on the ultimate development of essential hypertension has been extensively investigated by Lever et al. [41] using subpressor doses of angiotensin II. Despite minimal acute effect on blood pressure, these subpressor doses of angiotensin II ultimately led to chronic hypertension. To explore the possibility of a similar effect of amylin, more chronic studies are required which will involve achieving amylin levels in the range that would elicit a pressor response rather than studies with higher amylin levels which could decrease blood pressure via a lower affinity interaction with CGRP receptors. Plasma amylin levels in pathophysiological states [36] are within the range which would elicit a pressor rather than a hypotensive response, consistent with the hypothesis that in the pathophysiological context amylin tends to raise rather than reduce blood pressure. It is of interest that the only report of a patient with an amylin-secreting pancreatic islet cell tumour indicated that the patient had hypertension [42] . In contrast, patients with insulinomas do not have elevated blood pressure [43] . This provides further evidence for amylin rather than insulin being responsible for the hypertension associated with hyperinsulinaemic/hyperamylinaemic states.
In conclusion, we have shown that both amylin and salmon calcitonin, an agonist of the amylin receptor [9] , elicit pressor responses in the anaesthetised rat. Since the pressor response to amylin is blocked by peptide antagonists and is abolished by ganglion blockade we conclude that amylin acts at a receptor in the central nervous system. It is postulated that stimulation of a central amylin receptor leads to increased systemic blood pressure, possibly through the stimulation of the renin-angiotensin system. Furthermore, it is suggested that these modest effects in raising blood pressure could ultimately lead to the development of hypertension in states of chronic hyperinsulinaemia/hyperamylinaemia.
